Table 2.

Estimated 48-week risks, risk differences and risk ratios of COVID-19 outcomes by NRTI combination in HIV-positive individuals,^* CoVIHd Collaboration, Spain, February-December 2020

	Documented SARS-CoV-2 infection				Hospitalization due to COVID-19				ICU admission due to COVID-19				COVID-19 death
	No. events	Risks (95%CI), %	Risk Differences (95% CI), %	Risk Ratios (95% CI)	No. events	Risks (95%CI), %	Risk Differences (95% CI), %	Risk Ratios (95% CI)	No. events	Risks (95% CI), %	Risk Differences (95% CI), %	Risk Ratios (95% CI)	No. events	Risks (95% CI), %	Risk Differences (95% CI), %	Risk Ratios (95% CI)
TAF/FTC	923	4.3 (4.1, 4.6)	0	1.00	157	0.8 (0.7, 1.0)	0	1.00	17	0.09 (0.05,0.14)	0	1.00	9	0.06 (0.02, 0.11)	0	1.00
TDF/FTC	300	4.5 (3.9, 5.0)	0.16 (−0.48, 0.69)	1.04 (0.89, 1.17)	35	0.5 (0.4, 0.7)	−0.28 (−0.52, −0.08)	0.66 (0.43, 0.91)	2	0.03 (0.01,0.08)	−0.07 (−0.12,−0.004)	0.28 (0.11, 0.90)	1	0.02 (0.02, 0.09)	−0.04 (−0.07, 0.03)	0.37 (0.23, 1.90)
ABC/3TC	687	5.2 (4.8, 5.6)	0.89 (0.40, 1.34)	1.21 (1.09, 1.33)	147	1.1 (0.9, 1.2)	0.24 (0.02, 0.45)	1.29 (1.02, 1.58)	18	0.13 (0.08,0.19)	0.04 (−0.03,0.12)	1.39 (0.70, 2.80)	18	0.12 (0.07, 0.18)	0.06 (−0.01, 0.12)	2.02 (0.88, 6.12)
Other regimes	492	4.6 (4.1, 5.0)	0.24 (−0.27, 0.77)	1.06 (0.94, 1.18)	86	0.7 (0.5, 0.8)	−0.16 (−0.34,0.04)	0.81 (0.62, 1.05)	8	0.07 (0.02,0.12)	−0.02 (−0.09,0.04)	0.76 (0.23, 1.77)	9	0.06 (0.02, 0.11)	0 (−0.06, 0.06)	0.99 (0.34, 2.61)

^*Adjusted via inverse probability weighting for age (in years, linear and quadratic terms), sex (male, female), transmission category (heterosexual, homo/bisexual, injecting drug use, other), country of origin (Spain, other), CD4 (<350, 350–500, >500 cells/mm3), and hypertension, diabetes, chronic renal disease, cardiovascular disease, and treatment with immunosuppressants or corticosteroids.